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In 2007, the World Health Organization (WHO) and UNAIDS 
convened an international consultation of experts who 
represent a wide range of stakeholders, including government 
representatives, researchers, civil society representatives, 
gender experts, human rights and women’s health advocates, 
young people, funding agencies and implementing partners, 
to investigate the potential role of male circumcision in the 
prevention of HIV transmission. As a result, male circumcision 
is now recognised and recommended by WHO/UNAIDS as 
an additional and important strategy for the prevention of 
heterosexually acquired HIV infection in men in countries with 
a high prevalence of heterosexually transmitted HIV infection 
and low levels of male circumcision.1  
Following the results of rigorous scientific research and the 
WHO/UNAIDS recommendations, sub-Saharan countries 
including Kenya, Swaziland, Botswana and Uganda are 
implementing national male circumcision programmes to help 
prevent the spread of HIV.
Diverse advocacy groups such as Southern African HIV 
Clinicians Society and the Treatment Action Campaign 
(TAC) recognise voluntary medical male circumcision as an 
efficacious measure that can potentially reduce the national 
HIV epidemic in South Africa.
Multiple factors are associated with HIV infection, and 
biomedical studies may yield discordant results as a function 
of the scientific methodology used, such as study design, male 
circumcision status ascertainment and reporting of sexual 
behaviour. A major limitation of the review published in a 
recent SAMJ paper2 is that male circumcision was self-reported 
and not observed clinically. Furthermore, evidence from one 
study cannot and should not be generalised, especially in a 
domain as complex as the dynamics of sexually transmitted 
infections.
Acceptability of male circumcision among uncircumcised 
men in southern Africa is high, at about 60 - 70%.3 In a recent 
study conducted in Orange Farm, South Africa, 59% of the 
surveyed men to whom male circumcision was acceptable 
underwent the intervention.4 
Earlier studies show that in areas where male circumcision 
was practised, HIV prevalence was lower than where it was 
not practised.5,6 An analysis of the ecological and individual 
risk factors for HIV infection in four urban populations in sub-
Saharan Africa shows that this geographical correlation was 
not affected by variations in sexual behaviour: although high- 
risk sexual behaviour is more common in Cameroon, a country 
with high levels of male circumcision, HIV prevalence remains 
relatively low.7 
A methodologically sound, systematic review of 27 
observational studies on male circumcision and HIV revealed 
a reduced risk of HIV among circumcised men, namely 
about half that of uncircumcised men. It concluded that male 
circumcision was associated with significantly lower levels of 
HIV infection among men in sub-Saharan Africa, particularly 
among those at high risk of HIV.8
In biomedical research, randomised controlled trials are 
considered the gold standard for judging the benefits of 
an intervention, since the observed effect can be attributed 
more readily to the actual intervention than in the case of 
observational studies. Three recent randomised controlled 
trials, each conducted over a period of about 24 months,9-11 
demonstrated a reduced HIV acquisition risk of about 60% 
among circumcised men. 
Analyses from the extended follow-up of participants in 
a male circumcision randomised controlled trial conducted 
in Kisumu, Kenya, indicate that the protective effect of male 
circumcision was sustained, and possibly strengthened, for at 
least 42 months.12
In addition, mathematical and medical economics modelling 
studies have shown that the roll-out of male circumcision has 
a reasonable cost, is cost effective and can prevent millions of 
HIV infections in southern Africa.13-15
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In a recent survey conducted in Orange Farm it was found 
that 45% of men who declared themselves to be ‘circumcised’ 
still had an intact foreskin and were not clinically circumcised. 
HIV prevalence among these men was similar to that of 
uncircumcised men, but it was significantly lower among 
medically circumcised participants.4 This shows substantial 
bias with self-reported circumcision status in this population, 
and proves that the effectiveness of male circumcision stems 
from the removal of the foreskin, rather than cultural initiation 
practices. 
In all male circumcision randomised controlled trials, 
sexual behaviour was naturally taken into account as a factor 
associated with HIV acquisition. Evidence has shown that 
in the context of a randomised controlled trial, circumcision 
does not result in increased HIV risk behaviour, also called 
risk compensation. However, its continued monitoring, 
together with evaluation and intensification of HIV prevention 
messaging on an individual and population level, is necessary 
to support the efficacy of male circumcision.16 
Male circumcision is a cultural practice that can be changed: 
male circumcision was practised among the Zulus in the past 
and has become common in Korea. Furthermore, discussions 
with traditional circumcisers have indicated that collaboration 
is possible – medical male circumcision could therefore be 
combined with traditional initiation in order to minimise 
adverse events and morbidity associated with the intervention.
A randomised controlled trial in Orange Farm has 
shown that male circumcision markedly reduced human 
papillomavirus (HPV) acquisition by men, thus also reducing 
their female partners’ exposure to HPV. HPV is the main 
cause of cervical cancer among women. This means that male 
circumcision is also indirectly beneficial to women in reducing 
their exposure to sexually transmitted diseases other than 
HIV.17
Like all medical interventions, male circumcision is 
associated with benefits as well as with risks. Adverse effects 
that are associated with medical male circumcision and require 
treatment include pain, bleeding and infections. However, no 
deaths or mutilations were recorded during the 24 months of 
the three randomised controlled trials, despite the fact that 
about 10 000 male circumcisions were performed.9-11
Resuming sexual activity after male circumcision but before 
wound healing may increase the risk of HIV acquisition 
for both the men and their partners. Fortunately this risk 
applies only for a limited period of time (about 3 weeks), and 
imprudent behaviour may still be prevented by counselling. 
The risk also does not outweigh the far greater benefits of male 
circumcision.9-11
Male circumcision trials offer a unique context in which 
young men may be offered voluntary counselling and testing 
(VCT), as well as counselling on HIV prevention methods such 
as condom use.
Ethically, because male circumcision is effective and its 
cost reasonable, it has to be offered and made available to the 
general population in heterosexual HIV epidemic settings. 
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